W2 Pharmacokinetics & drug interactions of antihypertensive drugs Flashcards
(33 cards)
ADME Pharmacokinetics: (hypertensives)
What factors affect absorption?
- The route of administration (significant)
- Oral administration is the most common route for antihypertensive drugs
- Factors influencing drug absorption include the drug’s solubility, presence of food, and pH of the stomach and intestines.
- Some antihypertensive drugs may also be administered intravenously or topically
ADME Pharmacokinetics: (hypertensives)
What factors affect distribution?
- Antihypertensive drugs often target specific sites, such as blood vessels or the kidneys.
- Protein binding can affect drug distribution, as highly protein-bound drugs may be less available to exert their effects.
ADME Pharmacokinetics: (hypertensives)
What factors affect metabolism ?
- Most drugs are metabolised in the liver by hepatic enzymes.
- The cytochrome P450 enzyme system is responsible for metabolising many antihypertensive drugs.
- Drug metabolism can result in the formation of active or inactive metabolites.
- Genetic variations in drug-metabolising enzymes can influence an individual’s response to antihypertensive drugs.
ADME Pharmacokinetics: (hypertensives)
What factors affect excretion ?
- Kidneys play a crucial role in drug excretion.
- The rate of drug elimination depends on renal function, glomerular filtration rate, and other factors.
- Some drugs undergo active tubular secretion, which can also affect excretion
Treatments for hypertension
4 classes:
ACEi (ramipril)
ARB (losartan)
CCB (amlodipine)
Thiazide-like diuretic (indapamide)
Also:
Not included
beta-blocker
alpha-blocker
spironolactone
Which organ plays a crucial role in the excretion of antihypertensive drugs?
Kidneys
When do drug interactions occur?
When the presence of one drug affects the pharmacokinetics or pharmacodynamics of another drug
What are additive drug interactions?
When the combination of two drugs produces an effect equal to the sum of their individual effects.
What are synergistic drug interactions?
When the combination of drugs produces an effect greater than the sum of their individual effects
What are antagonistic drug interactions?
When the combination of drugs dimities or cancels out their individual effects
What is the class of drugs that end in ‘pril’?
ACE Inhibitors
Ramipril:
What are its 4 functions?
What are its side effects? (4)
Functions:
Prodrug= Inhibits ACE (Comp inhibitor)
Angiotensin ll dec so RAAS dec
1. Arterial and venous vasodilation
2. Decrease blood volume
3. Downregulation of sympathetic activity
4. Suppression of hypertrophy (cardiac and vascular)
Side effects:
* Hypotension
* Hyperkalaemia (potassium retention)
* Dry cough (up to 35%)
- ACE usually inhibits bradykinin
* Abnormal taste- Thiol moiety
Ramipril:
What are its ADME properties?
A= Take on empty stomach to improve absorption. 40-66% bioavailable depends on the drug
Short half-life <2 hours
D= Binds to tissue and plasma protein
M= Extensively metabolised (75%) in the liver by the cytochrome p450 enzyme CYP2C8
E= Urine
ACE inhibitors e.g. Ramipril example interactions
Drug-drug interactions
Concurrent use of ACE inhibitors and nonsteroidal anti-inflammatory drugs (NSAIDs) can reduce the effectiveness of ACE inhibitors and increase the risk of renal impairment, as NSAIDs can counteract the vasodilatory effects of ACE inhibitors.
Drug-food interactions
Consuming high-sodium meals or foods rich in potassium (such as bananas or oranges) can counteract the effects of ACE inhibitors by potentially increasing blood pressure or interfering with the balance of electrolytes.
Drug-herbal interactions
Taking St. John’s wort (Hypericum perforatum) along with ACE inhibitors may reduce the effectiveness of the medication due to St. John’s wort inducing DME that can accelerate the breakdown of ACE inhibitors.
CYPP450 inducers
Concurrent use of rifampin, an antibiotic and a potent cytochrome P450 inducer, with ACE inhibitors can accelerate the metabolism of ACE inhibitors, potentially reducing their effectiveness and requiring higher doses for adequate blood pressure control.
CYPP450 repressors
Concurrent use of fluoxetine, a selective serotonin reuptake inhibitor (SSRI) and a cytochrome P450 repressor, with ACE inhibitors can inhibit the metabolism of ACE inhibitors, potentially increasing their blood levels and leading to an increased risk of side effects.
Hypotension & hyperkalaemia
Aliskiren (↑ risk of renal impairment)
Allopurinol (↑ risk of hypersensitivity and haematological reactions)
Azathioprine (↑ risk of anaemia and/or leucopenia)
Everolimus (↑ risk of angioedema)
Lithium (↑ [lithium])
What are the class of drugs ending in ‘sartan’?
Angiotensin ll receptor blockers (ARBs)
Losartan
What is it used to treat?
What are the adverse effects?
An ARB used to treat hypertension, diabetic nephropathy and reduce the risk of stroke
* Hypotension
* Hyperkalaemia (due to potassium retention is mediated by the reduction of aldosterone)
* Renal impairment - GFR, creatinine levels
* Angio-oedema
* Dizziness
ADME of Losartan:
*Losartan is approximately 33% orally bioavailable. Losartan has a Tmaxof 1 hour and the active metabolite has a Tmaxof 3-4 hours
*The volume of distribution of losartan is 34.4±17.9L and 10.3±1.1L for the active metabolite (E-3174)
Losartan is 98.6-98.8% protein bound and the active metabolite is 99.7% protein bound in serum
** Metabolised in the liver (CYP450 2C9) **
*Oral radiolabelled losartan is 35% recovered in urine and 60% in faeces
*Active metabolite has a half life of 6-9 hours
Adverse effects:
*Hypotension
*Hemodialysis will not remove losartan or its active metabolite due to their high rates of protein binding
*190 known drug-drug interactions
*Food delays absorption, but not extent. Avoid potassium-containing salt substitutes
*The metabolism of Losartan can be decreased when combined with Ginkgo biloba.
*The metabolism of Losartan can be increased when combined with St. John’s Wort.
PHARMACOKINETIC drug interactions when taking losartan:
- Concomitant increased risk of hyperkalaemia, hypotension, and renal impairment (angiotensin-converting enzyme (ACE) inhibitorsandaliskiren)
- Volume depletion and a risk of hypotension (previous diuretics)
- Lithium (reversible increases in serum lithium concentrations and toxicity)
- Attenuation of antihypertensive effect, worsening of renal function, including possible acute kidney injury, and hyperkalaemia (nonsteroidal anti-inflammatory drugs and COX-2 inhibitors)
- Increased risk of hyperkalaemia (amiloride, ciclosporin, eplerenone, heparins, potassium canrenoate, potassium salts, spironolactone, tacrolimus, triamterene,trimethoprim)
- Enhanced hypotensive effect (Alpha-blockers, alprostadil, antipsychotics, anxiolytics, beta-blockers, baclofen, calcium channel blockers, clonidine, co-beneldopa, co-careldopa, diazoxide, hydralazine, hypnotics, levodopa, methyldopa, minoxidil, monoamine oxidase inhibitors, moxisylyte, moxonidine, nitrates, SGLT2 inhibitors, sodium nitroprusside, tizanidine, tricyclic antidepressants)
Adverse effects:
Hypotension
Hyperkalaemia (due to potassium retention is mediated by the reduction of aldosterone)
Renal impairment - GFR, creatinine levels
Angio-oedema
Dizziness
What drug class of antihypertensive ends in ‘dipine’?
Dihydropyridine Calcium channel blockers (CCB)
e.g. Amlodipine, Felodipine
Amlodipine
- Used to treat hypertension and angina
- Does not change SAN function or AV conduction BUT dec Vascular smooth muscle contractility and dec BP
Depolarisation or actions of PKA (via β-adrenoreceptor activation) cause Ca2+ influx via L-type channels.
Lead to contraction.
Ca2+ channel blockers (CCBs) bind to the α subunit of L-type channels.
Prevents Ca2+ influx via depolarisation or PKA activation
Reduced cardiomyocyte or VSMC contraction
What are the effects of CCBs like amlodipine?
1. Cardiac
2. Vascular
- Dec Myocardial contractility, force myocardial contraction and dec conduction velocity (depends on firing of SA and AV nodes)
- Vasodilate peripheral blood vessels
What are the TWO TYPES OF CCB?
- dihydropyridine (…dipine drugs) – act on smooth muscle cells of blood vessels, decrease vascular resistance and ↓↓bp (vascular specific)
- non-dihydropyridine – greater effect on heart, less effective for vasodilation vessels e.g. diltiazem and verapamil
(cardiac specific)
CCB ADME:
Bioavailability: Amlodipine is orally administrated with a bioavailability of 64–90%.
A: Amlodipine reach peak plasma concentration (tmax) 6–12h after administration, while steady state plasma concentrations will be reached within 7–8days of daily dosing.
D: Amlodipine has a high volume of distribution (21L/kg) and a large proportion of the dose is distributed in the tissue with ~ 90% of the circulating drug being bound to the plasma membrane.
M: Amlodipine is extensively metabolised in the liver into its inactive metabolites viaCYP3A4/5.
E: Amlodipine is slowly cleared with an elimination half-life of 40 to 60h. If discontinued, BP returned to baseline after 1week. Urine is the major route of elimination. Amlodipine is converted to inactive metabolites (60%), which are excreted into the urine while 10% of the excreted drug remains unchanged. Amlodipine is converted from dihydropyridinebmoiety to a pyridine derivative (M9). Fecal excretion accounts for 20–25% of the dose
What are the adverse effects of dihydropyridine CCBs?
- Bradycardia
- Abdominal pain, nausea, and vomiting.
- Angio-oedema.
- Dizziness.
- Drowsiness.
- Flushing.
- Gingival hyperplasia.
- Headache.
- Myalgia.
- Palpitations and tachycardia.
- Peripheral oedema.
- Syncope
Reflex tachycardia – sympathetic nervous system detect ↓BP so ↑↑HR